Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Pediatrics/Neonatology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Leukemia (Pediatric) Clinical Trials

A listing of Leukemia (Pediatric) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (239) clinical trials

Study of Clofarabine Etoposide Cyclophosphamide [CEC] Liposomal Vincristine (VCR) Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study part based on when you join this study. At least 1 group of up to 6 participants is planned to be enrolled in the safety lead-in part of ...

Phase

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

Upon meeting the eligibility requirements and enrolling on study, subjects will undergo apheresis to obtain the T cells for the generation of the CD19 CAR+ T cells. In patients with a prior history of allogeneic HCT, the T cells obtained are of donor origin. The T cells are isolated from ...

Phase

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

The aim of the research in this study is to make participants' transplant safer by reducing the risk of developing GVHD and GVHD-related complications by giving participants a dose of the drug tocilizumab in addition to the standard approach for GVHD prevention. Tocilizumab reduces the risk of inflammation by blocking ...

Phase

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

STUDY OBJECTIVES Primary Objective To determine the safety and tolerability of autologous iC9-CAR19 T cells administered to adult and pediatric subjects with relapsed or refractory CD19+ Acute Lymphoblastic Leukemia (ALL). Secondary Objectives To identity a recommended phase 2 dose (RP2D) of iC9-CAR19 T cells in adult and pediatric subjects with ...

Phase

Transplantation of Ex Vivo Expanded UCB-derived Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients

Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone marrow and regenerating a full array of hematopoietic cell lineages with early and late repopulating ability in a timely fashion. A major drawback of Umbilical ...

Phase

A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in pediatric or adolescent subjects.

Phase

Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

The duration of active protocol intervention is approximately 12-15 months from the screening visit. The protocol will require approximately 12-18 months to complete enrollment.Approximately 39 enrolled patients to reach at least 35 infused patients, with the ultimate goal of 15 patients in the high tumor burden cohort (Cohort A). Inclusion ...

Phase N/A

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

In this research study, the investigators are studying the optimal dose of the drug MLN 9708 when given with a standard multi-drug regimen. In the first part of the study, up to 18 participants will be enrolled at different doses of MLN 9708. Once the maximally tolerated (highest, safest dose) ...

Phase

Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia

Study Drug Administration Each cycle is 21 days (+/- 7 days). Intensive Chemotherapy (Cycles 1 and 3): If you are found to be eligible to take part in this study, you will receive hyper-CVAD during Cycles 1 and 3 as follows: On Days 1-3, you will receive cyclophosphamide by vein ...

Phase

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL

Patients will be randomized in a 1:1 ratio to receive either one cycle of blinatumomab or one block of standard high-risk consolidation chemotherapy. Blinatumomab is administered as a continuous intravenous infusion (CIVI). One cycle of blinatumomab treatment includes 4 weeks of CIVI of blinatumomab. After completing consolidation therapy, the patients ...

Phase